Results 101 to 110 of about 113,475 (131)

Novel therapeutic approaches for treatment of COVID-19. [PDF]

open access: yesJ Mol Med (Berl), 2020
Hossein-Khannazer N   +5 more
europepmc   +1 more source

Prospective randomized open-label comparative study of immunogenicity after subunit and polymeric subunit influenza vaccines administration among mothers and infants. [PDF]

open access: yesHum Vaccin Immunother, 2018
Kostinov MP   +7 more
europepmc   +1 more source

Dendritic cell-based vaccines in treating recurrent herpes labialis: Results of pilot clinical study. [PDF]

open access: yesHum Vaccin Immunother, 2016
Leplina O   +5 more
europepmc   +1 more source

Enhancing Aseptic Inflammation Resolution with 1-(2-Ethoxyethyl)-4-(pent-1-yn-1-yl)piperidin-4-yl Propionate: A Novel β-Cyclodextrin Complex as a Therapeutic Agent. [PDF]

open access: yesMolecules
Zhumakova S   +11 more
europepmc   +1 more source

Immunoadjuvanted influenza vaccine immunogenicity in children with type 1 diabetes over two consecutive seasons. [PDF]

open access: yesFront Immunol
Kostinov MP   +12 more
europepmc   +1 more source

Progress on the research and development of plague vaccines with a call to action. [PDF]

open access: yesNPJ Vaccines
Williamson ED   +5 more
europepmc   +1 more source

Impact of the azoximer bromide concomitant therapy on patient outcomes in patients with melanoma.

Journal of Clinical Oncology, 2021
e21574 Background: Immunomodulators are used in the treatment of patients with melanoma. However, their role as anticancer therapeutic agents requires further investigation. Azoximer bromide (AB) is a well-tolerated immunomodulator that has been used in cases of melanoma.
Natalya Shendaleva   +9 more
openaire   +1 more source

Evaluation of Potential Prophylactic and Therapeutic Effect of Azoximer Bromide (Polyoxidonium) on Experimental Cryptosporidiosis in Immunocompromised Mice

open access: yesParasitologists United Journal, 2021
Amany Atia   +5 more
exaly   +2 more sources

Impact of the azoximer bromide concomitant therapy on outcomes in patients with soft tissue sarcoma.

Journal of Clinical Oncology, 2021
e23534 Background: Immunomodulators are used in the management of patients with soft tissue sarcoma, (STS). However, the precise mechanism behind their benefits in anticancer therapy effects have yet to be determined. We assessed the impact of the immunomodulator azoximer bromide (AB) as a prognostic factor for survival when used concomitant with ...
Aleksei Viktorovich Novik   +9 more
openaire   +1 more source

Home - About - Disclaimer - Privacy